GONUTS has been updated to MW1.31 Most things seem to be working but be sure to report problems.

Have any questions? Please email us at ecoliwiki@gmail.com

PMID:21440438

From GONUTS
Jump to: navigation, search
Citation

Robb, SA, Sewry, CA, Dowling, JJ, Feng, L, Cullup, T, Lillis, S, Abbs, S, Lees, MM, Laporte, J, Manzur, AY, Knight, RK, Mills, KR, Pike, MG, Kress, W, Beeson, D, Jungbluth, H, Pitt, MC and Muntoni, F (2011) Impaired neuromuscular transmission and response to acetylcholinesterase inhibitors in centronuclear myopathies. Neuromuscul. Disord. 21:379-86

Abstract

Many clinical features of autosomal centronuclear myopathies (CNM) and X-linked myotubular myopathy (XLMTM) are common to congenital myasthenic syndromes (CMS). We describe three children whose clinical and electrophysiological findings originally suggested CMS, in whom CNM was diagnosed pathologically, though not yet genetically characterised. A fourth case, with XLMTM, also showed electrophysiological features of a neuromuscular transmission defect. Three (including the XLMTM case) showed improved strength with acetylcholinesterase inhibitor treatment. We also studied neuromuscular junction structure and function in the MTM1 knockdown zebrafish model of XLMTM, demonstrating abnormal neuromuscular junction organization; anticholinesterase therapy resulted in marked clinical response. These observations suggest that a neuromuscular transmission defect may accompany CNM and contribute to muscle weakness. Muscle biopsy should be considered in infants suspected to have CMS, especially if treatment response is incomplete, or no CMS gene mutation is identified. Treatment with acetylcholinesterase inhibitors may benefit some CNM patients. This warrants further confirmation.

Links

PubMed Online version:10.1016/j.nmd.2011.02.012

Keywords

Adolescent; Animals; Biopsy; Child; Cholinesterase Inhibitors/pharmacology; Cholinesterase Inhibitors/therapeutic use; Disease Models, Animal; Electromyography; Female; Gene Knockout Techniques; Humans; Infant; Male; Muscle, Skeletal/pathology; Myopathies, Structural, Congenital/drug therapy; Myopathies, Structural, Congenital/genetics; Myopathies, Structural, Congenital/physiopathology; Neuromuscular Junction/drug effects; Neuromuscular Junction/physiopathology; Protein Tyrosine Phosphatases, Non-Receptor/genetics; Pyridostigmine Bromide/pharmacology; Pyridostigmine Bromide/therapeutic use; Synaptic Transmission/drug effects; Synaptic Transmission/physiology; Treatment Outcome; Zebrafish; Zebrafish Proteins/genetics

Significance

Annotations

Gene product Qualifier GO Term Evidence Code with/from Aspect Extension Notes Status

DANRE:F8W5H1

involved_in

GO:0007528: neuromuscular junction development

ECO:0000315: mutant phenotype evidence used in manual assertion

ZFIN:ZDB-MRPHLNO-100325-1

P

Seeded From UniProt

complete

DANRE:Q32PM3

involved_in

GO:0007528: neuromuscular junction development

ECO:0000315: mutant phenotype evidence used in manual assertion

ZFIN:ZDB-MRPHLNO-100325-1

P

Seeded From UniProt

complete


See also

References

See Help:References for how to manage references in GONUTS.